Both Tal-DP and Tal-D yielded longer progression-free survival than DPd in those who had received at least one line of therapy
THURSDAY, June 18, 2026 (HealthDay News) — Among patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy, talquetamab plus daratumumab and pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) yield longer progression-free survival than daratumumab plus pomalidomide and dexamethasone (DPd), according to a study published online June 13 in the New England Journal of Medicine.
Roberto Mina, M.D., from the University of Turin in Italy, and colleagues randomly assigned patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy to receive Tal-DP, Tal-D, or DPd in a phase 3 trial (287, 287, and 290 patients, respectively).
The researchers found that at a median follow-up of 24.6 months (interim analysis), progression-free survival was significantly longer with Tal-DP and Tal-D than with DPd (24-month estimate, 81.3 and 77.6 percent, respectively, versus 51.2 percent; hazard ratios for disease progression or death, 0.28 and 0.33, respectively). Compared with DPd, the overall response was higher with Tal-DP and Tal-D, as was complete response or better and measurable residual disease-negative complete response. At 24 months, overall survival was 89.2 and 87.9 percent versus 79.1 percent with Tal-DP and Tal-D, respectively, versus DPd (hazard ratios for death, 0.47 and 0.51, respectively).
“When multiple myeloma comes back, it can be incredibly difficult for patients and their families,” coauthor Peter M. Voorhees, M.D., from the Atrium Health Levine Cancer Institute at Wake Forest University School of Medicine in Charlotte, North Carolina, said in a statement. “This study suggests we may be able to offer a treatment to give patients more time, better disease control, and most importantly, renewed hope.”
Several authors disclosed ties to biopharmaceutical companies, including Johnson & Johnson, which manufactures talquetamab and funded the study.
Abstract/Full Text (subscription or payment may be required)
Response to Autologous HSCT Durable for Patients With Systemic Sclerosis 
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment 
Early Survivorship Care Linked to Improved Outcomes in Head, Neck Cancer 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
